68Ga PSMA PET Imaging for the Treatment of Advanced Liver Cancer

• Status: Recruiting
• Trial end date: 2025-12-30
• Target enrollment: 0
• Participant gender: All

Summary

This phase II trial tests whether 68-Gallium prostate specific membrane antigen (68Ga-PSMA) positron emission tomography (PET) imaging can improve the diagnosis and management of liver cancer that has spread to other parts of the body (advanced). PSMA is a protein that appears in large amounts on the surface of liver cancer cells. The radioactive chemical compound (68Ga-PSMA) has been designed to circulate through the body and attach itself to the PSMA protein on liver cancer cells. A PET scan is then used to detect the location of the tumor cells. 68Ga-PSMA PET may improve upon the diagnosis and management of liver cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mayo Clinic
• Treatments: Edetic Acid; Gallium 68 PSMA-11

Criteria

Inclusion Criteria:

• Patient with pathologically confirmed HCC not amenable to curative resection, transplantation or ablative therapies

• Have radiographically measurable disease by RECIST

• Eligible for atezolizumab/bevacizumab front line therapy

• Male or female with age greater than 18 years, with the capacity and willingness to provide written informed consent

Exclusion Criteria:

• Pregnant and/or breast-feeding patients. A negative pregnancy test within 48 hours of the PET scan

• Patients with higher than the weight/size limitations of PET/CT scanner